BGB 26808
Alternative Names: BGB-26808Latest Information Update: 29 Sep 2023
At a glance
- Originator BeiGene
- Class Antineoplastics
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 07 Sep 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Combination therapy) in Australia (PO) (NCT05981703)
- 07 Sep 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Combination therapy) in New Zealand (PO) (NCT05981703)
- 07 Sep 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy) in New Zealand (PO) (NCT05981703)